Trastuzumab deruxtecan (TDXD) and datopotamab deruxtecan (Dato-DXd) share the same cytotoxic payload, yet Dato-DXd has a much lower rate of interstitial lung disease (ILD). This indicates the toxicity is driven by the antibody-antigen interaction, not the payload itself.

Interstitial Lung Disease (ILD) is a significant risk with TDXD. However, a history of a completely resolved grade 1 event does not automatically preclude a patient from receiving the drug again. Clinicians may consider a re-challenge, balancing the risk against the lack of other viable therapies.

When debating immunotherapy risks, clinicians separate manageable side effects from truly life-altering events. Hypothyroidism requiring a daily pill is deemed acceptable, whereas toxicities like diabetes or myocarditis (each ~1% risk) are viewed as major concerns that heavily weigh on the risk-benefit scale for early-stage disease.

The enzalutamide arms saw discontinuation rates of 20-25% due to adverse events. This high rate reflects a different risk calculation for patients who feel healthy and are asymptomatic. Unlike in advanced disease where patients tolerate more toxicity, this population has a very low threshold for side effects, making early intervention a significant trade-off.

With highly effective treatments like CAR-T and bispecifics moving into earlier lines of therapy for multiple myeloma, the clinical focus must evolve. While efficacy benchmarks have been met, the next advancement requires vigilant attention to safety, particularly infection risks and other side effects of new paradigms.

The 'safety first' mandate in drug development is flexible. For cancers like leukemia with high cure rates, highly aggressive therapies with severe side effects are deemed acceptable. The risk-benefit calculation shifts dramatically when a cure, not just management, is the goal.

Adopting T-DXd in early-stage breast cancer requires frequent chest CT scans to monitor for potentially fatal interstitial lung disease (ILD), a practice not standard for current therapies. This presents significant new logistical challenges, including securing insurance approvals, managing patient access, and increasing the overall burden of care.

Contrary to initial fears, both clinical trial and real-world data show that patients experiencing asymptomatic, grade 1 interstitial lung disease (ILD) from TDXD can be safely retreated. This allows patients to continue benefiting from a highly effective therapy without undue risk.

While oncologists focus on the low 4% rate of Interstitial Lung Disease (ILD) from neoadjuvant TDXD, surgeons worry this complication could prevent patients from reaching potentially curative surgery, drawing parallels to issues seen with neoadjuvant immunotherapy.